|
|
| Fosphenytoin in a Nutshell |
| |
| |
Markets |
| |
- Fosphenytoin is an approved injectable therapy marketed under the brand names of Cerebyx and Ativan
- About 152,000 cases of status epilepticus occur each year in the U.S., resulting in annual patient costs of $3.8 - $7.0 billion
- Cerebyx sales generated $71 million in revenue in 2006
|
| |
Product Advantages |
| |
- Current formulation of Cerebyx requires refrigeration, making it difficult to use in emergency settings
- Captisol Enabled Fosphenytoin for either intravenous or intramuscular has been designed to not require refrigeration
- We believe these formulations can be stored at room temperature in bags or syringes
|
| |
Development Status |
| |
- Completed two pivotal studies in 90 patients
- NDA filing anticipated in Q4 2008
|
| Updated: May 29, 2008 | |
